Reproductive outcomes and nononcologic complications after radioactive iodine ablation for well-differentiated thyroid cancer

Thyroid

Volumn 25, Issue 1, 2015, Pages 133-138

  Wu, James X ^a   Young, Stephanie ^a   Ro, Kevin ^a   Li, Ning ^a   Leung, Angela M ^a   Chiu, Harvey K ^a   Harari, Avital ^a   Yeh, Michael W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE;

ABLATION THERAPY; ADOLESCENT; ADULT; AGE; ARTICLE; BIRTH RATE; CANCER REGISTRY; CHARLSON COMORBIDITY INDEX; CHILDBIRTH; COHORT ANALYSIS; DIFFERENTIATED THYROID CANCER; FEMALE; FOLLOW UP; HUMAN; LIVE BIRTH; MAJOR CLINICAL STUDY; MARRIAGE; NASOLACRIMAL DUCT STENOSIS; POPULATION; PREGNANCY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOCIAL STATUS; STENOSIS; AGED; CARCINOMA, PAPILLARY; MALE; MIDDLE AGED; THYROID NEOPLASMS; THYROIDECTOMY;

ADULT; AGED; BIRTH RATE; CARCINOMA, PAPILLARY; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PREGNANCY; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 84920806254     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2014.0343     Document Type: Article

References (28)

1. National Cancer Institute. Bethesda, MD. SEER Stat Fact Sheets: Thyroid Cancer. Available at: http://seer.cancer.gov/statfacts/html/thyro.html (Last accessed November 16, 2013).
2. Van Nostrand D 2009 The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid 19:1381-1391.
3. Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, Maurer MS, McIver B, Mullan BP, Oberg AL, Powell CC, van Heerden JA, Goellner JR 2002 Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 26:879-885.
4. Nixon IJ, Ganly I, Patel SG, Palmer FL, Di Lorenzo MM, Grewal RK, Larson SM, Tuttle RM, Shaha A, Shah JP 2013 The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification. Thyroid 23:683-694.
5. Haymart MR, Banerjee M, Yang D, Stewart AK, Sisson JC, Koenig RJ, Doherty GM, Griggs JJ 2013 Variation in the management of thyroid cancer. J Clin Endocrinol Metab 98:2001-2008.
6. Haymart MR, Muenz DG, Stewart AK, Griggs JJ, Banerjee M 2013 Disease severity and radioactive iodine use for thyroid cancer. J Clin Endocrinol Metab 98:678-686.
7. Schuessler KM, Banerjee M, Yang D, Stewart AK, Doherty GM, Haymart MR 2013 Surgeon training and use of radioactive iodine in stage I thyroid cancer patients. Ann Surg Oncol 20:733-738.
8. Papaleontiou M, Banerjee M, Yang D, Sisson JC, Koenig RJ, Haymart MR 2013 Factors that influence radioactive iodine use for thyroid cancer. Thyroid 23:219-224.
9. Haymart MR, Banerjee M, Stewart AK, Koenig RJ, Birkmeyer JD, Griggs JJ 2011 Use of radioactive iodine for thyroid cancer. JAMA 306:721-728.
10. Iyer NG, Morris LGT, Tuttle RM, Shaha AR, Ganly I 2011 Rising incidence of second cancers in patients with lowrisk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer 117:4439-4446.
11. Alexander C, Bader JB, Schaefer A, Finke C, Kirsch CM 1998 Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med 39: 1551-1554.
12. Sawka AM, Lakra DC, Lea J, Alshehri B, Tsang RW, Brierley JD, Straus S, Thabane L, Gafni A, Ezzat S, George SR, Goldstein DP 2008A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clin Endocrinol (Oxf) 69:479-490.
13. Sawka AM, Lea J, Alshehri B, Straus S, Tsang RW, Brierley JD, Thabane L, Rotstein L, Gafni A, Ezzat S, Goldstein DP 2008A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors. Clin Endocrinol (Oxf) 68:610-617.
14. Yost K, Perkins C, Cohen R, Morris C, Wright W 2001 Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control 12:703-711.
15. Garsi JP, Schlumberger M, Rubino C, Ricard M, Labbe M, Ceccarelli C, Schvartz C, Henri-Amar M, Bardet S, de Vathaire F 2008 Therapeutic administration of 131I for differentiated thyroid cancer: radiation dose to ovaries and outcome of pregnancies. J Nucl Med 49:845-852.
16. Koutras DA 1997 Disturbances of menstruation in thyroid disease. Ann NY Acad Sci 816:280-284.
17. Ceccarelli C, Bencivelli W, Morciano D, Pinchera A, Pacini F 2001 131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study. J Clin Endocrinol Metab 86:3512-3515.
18. Martin JA, Hamilton BE, Ventura SJ, Osterman MJK, Mathews TJ 2013 Births: Final data for 2011. Natl Vital Stat Rep 62:1-69, 72.
19. Wallenius M, Skomsvoll JF, Irgens LM, Salvesen KA, Nordvag BY, Koldingsnes W, Mikkelsen K, Kaufmann C, Kvien TK 2012 Parity in patients with chronic inflammatory arthritides childless at time of diagnosis. Scand J Rheumatol 41:202-207.
20. Erichsen MM, Husebye ES, Michelsen TM, Dahl AA, Lovas K 2010 Sexuality and fertility in women with Addison's disease. J Clin Endocrinol Metab 95:4354-4360.
21. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Hauger BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
22. Joffe M 2000 Time trends in biological fertility in Britain. Lancet 355:1961-1965.
23. Kloos RT, Duvuuri V, Jhiang SM, Cahill KV, Foster JA, Burns JA 2002 Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin Endocrinol Metab 87:5817-5820.
24. Rosario PW, Calsolari MR 2013 Salivary and lacrimal gland dysfunction after remnant ablation with radioactive iodine in patients with differentiated thyroid carcinoma prepared with recombinant human thyrotropin. Thyroid 23:617-619.
25. Sun GEC, Hatipoglu B 2013 Epiphora after radioactive iodine ablation for thyroid cancer. Thyroid 23:243-245.
26. Metso S, Auvinen A, Huhtala H, Salmi J, Oksala H, Jaatinen P 2007 Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer 109:1972-1979.
27. Baxter NN, Sutradhar R, DelGuidice ME, Forbes S, Paszat LF, Wilton AS, Urbach D, Rabeneck L 2013A populationbased study of rates of childbirth in recurrence-free female young adult survivors of Non-gynecologic malignancies. BMC Cancer 13:30.
28. Krassas GE, Poppe K, Glinoer D 2010 Thyroid function and human reproductive health. Endocr Rev 31:702-755.